1. Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted alpha-particle therapy. J Nucl Med. 2005;46(Suppl 1):199S–204S.
2. Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W, et al. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med. 2017;58(10):1624–163.
3. Elgqvist J, Frost S, Pouget JP, Albertsson P. The potential and hurdles of targeted alpha therapy—clinical trials and beyond. Front Oncol. 2014;3:324.
4. Bruland OS, Larsen RH. Radium revisited. In: Bruland OS, Flagstad T, editors. Targeted cancer therapies: an odyssey. Ravnetrykk No. 29: University Library of Tromso; 2003. p. 195–202.
5. “Preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning” US 6635234
http://patft.uspto.gov